Change set

Pick exam & year, then Go.

Question map
Not attempted Correct Incorrect ★ Bookmarked
Loading…
Q9 (UPPCS/2021) Science & Technology › New Materials, Energy & Environment-linked Tech

At the time of second wave of COVID-19 Pandemic, which institute had demonstrated the conversion of nitrogen generator into oxygen generator ?

Explanation

During the second wave of the COVID-19 pandemic in April 2021, IIT Bombay demonstrated a creative solution to address oxygen shortages by converting a Nitrogen generator into an Oxygen generator. The project, led by Professor Milind Atrey, utilized the existing Pressure Swing Adsorption (PSA) technology found in industrial nitrogen plants. By replacing the Carbon Molecular Sieve (CMS)—which adsorbs oxygen to produce nitrogen—with Zeolite Molecular Sieve (ZMS), the unit was modified to adsorb nitrogen and produce oxygen instead. Initial tests showed that the converted plant could produce oxygen with 93-96% purity at 3.5 atmospheric pressure. This innovation provided a rapid, cost-effective way to repurpose industrial infrastructure for medical emergencies.

✓ Thank you! We'll review this.

SIMILAR QUESTIONS

UPPCS · 2024 · Q70 Relevance score: 0.09

The recent global pause during COVID-19 pandemic was caused due to :

IAS · 2022 · Q69 Relevance score: -2.82

In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements : 1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform. 2. Sputnik V vaccine is manufactured using vector based platform. 3. COVAXIN is an inactivated pathogen based vaccine. Which of the statements given above are correct ?

CDS-II · 2022 · Q66 Relevance score: -3.83

During 2020 - 21, when India was passing through the adverse effects of COVID-19, which one of the following sectors witnessed positive growth?

CDS-II · 2020 · Q56 Relevance score: -4.33

Which one of the following Indian institutes was approved by the Drugs Controller General of India for conducting human trials of the Oxford-AstraZeneca Covid-19 vaccine candidate?